Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ungaro

Showing results (161-170 of 386) with videos related to

Pageof 39
Sort By:
Journal of Crohn'S & Colitis|October 9, 2025
Disease duration impacts intestinal gene expression profiles in Crohn's disease but not in ulcerative colitisSusanne Ibing, Christopher Tastad, Bernhard Y Renard, et al.
Journal of Crohn'S & Colitis|November 24, 2020
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD RegistryManasi Agrawal, Erica J Brenner, Xian Zhang, et al.
Inflammatory Bowel Diseases|February 12, 2026
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisDavid T Rubin, Silvio Danese, Hiroshi Nakase, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 17, 2020
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC ConsortiumMarc Fenster, Quazim A Alayo, Aava Khatiwada, et al.
Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Journal of Crohn'S & Colitis|April 28, 2025
A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's diseaseAmanda M Johnson, Manar Askar, Seema Belani, et al.
The Lancet. Gastroenterology & Hepatology|April 5, 2025
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial designSailish Honap, Nelly Agrinier, Joana Torres, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2020
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative ColitisParakkal Deepak, Quazim A Alayo, Aava Khatiwada, et al.
Archives of Iranian Medicine|February 7, 2022
Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD MedicationsAli Reza Sima, Bahar Saberzadeh-Ardestani, Homayoon Vahedi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 15, 2023
Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort StudyAriela K Holmer, Jiyu Luo, Kirk B Russ, et al.
Pageof 39

Showing results (161-170 of 386) with videos related to

Sort By:
Pageof 39
Journal of Crohn'S & Colitis|October 9, 2025
Disease duration impacts intestinal gene expression profiles in Crohn's disease but not in ulcerative colitisSusanne Ibing, Christopher Tastad, Bernhard Y Renard, et al.
Journal of Crohn'S & Colitis|November 24, 2020
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD RegistryManasi Agrawal, Erica J Brenner, Xian Zhang, et al.
Inflammatory Bowel Diseases|February 12, 2026
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisDavid T Rubin, Silvio Danese, Hiroshi Nakase, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 17, 2020
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC ConsortiumMarc Fenster, Quazim A Alayo, Aava Khatiwada, et al.
Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Journal of Crohn'S & Colitis|April 28, 2025
A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's diseaseAmanda M Johnson, Manar Askar, Seema Belani, et al.
The Lancet. Gastroenterology & Hepatology|April 5, 2025
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial designSailish Honap, Nelly Agrinier, Joana Torres, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2020
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative ColitisParakkal Deepak, Quazim A Alayo, Aava Khatiwada, et al.
Archives of Iranian Medicine|February 7, 2022
Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD MedicationsAli Reza Sima, Bahar Saberzadeh-Ardestani, Homayoon Vahedi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 15, 2023
Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort StudyAriela K Holmer, Jiyu Luo, Kirk B Russ, et al.
Pageof 39